![Page 1: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/1.jpg)
NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS
V. ALONSO
SERVICIO DE ONCOLOGIA MEDICA
H. U. MIGUEL SERVET
![Page 2: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/2.jpg)
![Page 3: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/3.jpg)
LASTEST PROGRESS IN NENs
✓NEW CLASSIFICATION WHO PanNENs 2017
✓EPIDEMIOLOGY
✓DIAGNOSIS.- 68Ga PET-TC
✓TREATMENT OF NENs
![Page 4: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/4.jpg)
LASTEST PROGRESS IN NENs
✓NEW CLASSIFICATION WHO PanNENs 2017
✓EPIDEMIOLOGY
✓DIAGNOSIS.- 68Ga PET-TC
✓TREATMENT OF NENs
![Page 5: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/5.jpg)
CATEGORIES OF TREATMENT
✓SOMATOSTATIN ANALOGUES✓Octreotide✓ Lanreotide
✓TELOTRISTAT
✓PEPTIDE RECEPTOR RADIONUCLIDE THERAPY✓
90Y-DOTATE/DOTATOC✓
177Lu-DOTATE
✓mTOR inhibitors✓ Everolimus✓ Temsirolimus
✓TKI – Angiogenesis✓ Sunitinib✓Bevacizumab
✓CYTOTOXIC CHEMOTHERAPY✓ Streptozocin-based✓ Temozolomide-based
✓IMMUNOTHERAPY✓ Interferon✓PD-1 inh.
✓LIVER-DIRECTED THERAPY✓ TAE/TACE✓ SIRT
![Page 6: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/6.jpg)
CATEGORIES OF TREATMENT
✓SOMATOSTATIN ANALOGUES✓Octreotide✓ Lanreotide
✓TELOTRISTAT
✓PEPTIDE RECEPTOR RADIONUCLIDE THERAPY✓
90Y-DOTATE/DOTATOC✓
177Lu-DOTATE
✓mTOR inhibitors✓ Everolimus✓ Temsirolimus
✓TKI – Angiogenesis✓ Sunitinib✓Bevacizumab
✓CYTOTOXIC CHEMOTHERAPY✓ Streptozocin-based✓ Temozolomide-based
✓IMMUNOTHERAPY✓ Interferon✓PD-1 inh.
✓LIVER-DIRECTED THERAPY✓ TAE/TACE✓ SIRT
![Page 7: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/7.jpg)
ANTI-TUMOR EFFECTS OF LANREOTIDE FOR PANCREATIC AND INTESTINAL NEUROENDOCRINE TUMOURS: THE CLARINET OPEN-LABEL EXTENSION STUDY
Caplin M et al. Endocrine-Related Cancer 2016; 23: 191-99
![Page 8: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/8.jpg)
ANTI-TUMOR EFFECTS OF LANREOTIDE FOR PANCREATIC AND INTESTINAL NEUROENDOCRINE TUMOURS: THE CLARINET OPEN-LABEL EXTENSION STUDY
Caplin M et al. Endocrine-Related Cancer 2016; 23: 191-99
138 p eligible - 88 p included41 LAN-----LAN47 PBO -----LAN
Treatment exposureLAN----------LAN-----------40 monthsPBO (SD)----LAN-----------18 monthsPBO (PD)----LAN-----------13 months
![Page 9: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/9.jpg)
ANTI-TUMOR EFFECTS OF LANREOTIDE FOR PANCREATIC AND INTESTINAL NEUROENDOCRINE TUMOURS: THE CLARINET OPEN-LABEL EXTENSION STUDY
Placebo (PD)---------LAN
Caplin M et al. Endocrine-Related Cancer 2016; 23: 191-99
![Page 10: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/10.jpg)
![Page 11: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/11.jpg)
CATEGORIES OF TREATMENT
✓SOMATOSTATIN ANALOGUES✓Octreotide✓ Lanreotide
✓TELOTRISTAT
✓PEPTIDE RECEPTOR RADIONUCLIDE THERAPY✓
90Y-DOTATE/DOTATOC✓
177Lu-DOTATE
✓mTOR inhibitors✓ Everolimus✓ Temsirolimus
✓TKI – Angiogenesis✓ Sunitinib✓Bevacizumab
✓CYTOTOXIC CHEMOTHERAPY✓ Streptozocin-based✓ Temozolomide-based
✓IMMUNOTHERAPY✓ Interferon✓PD-1 inh.
✓LIVER-DIRECTED THERAPY✓ TAE/TACE✓ SIRT
![Page 12: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/12.jpg)
![Page 13: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/13.jpg)
≥4 BM per day while stabledose SSAs for 3 months
<12 BM, no dehydration
IK>60%
Liver function tests
![Page 14: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/14.jpg)
RECOMMENDED DOSE 250 mg TID
![Page 15: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/15.jpg)
CATEGORIES OF TREATMENT
✓SOMATOSTATIN ANALOGUES✓Octreotide✓ Lanreotide
✓TELOTRISTAT
✓PEPTIDE RECEPTOR RADIONUCLIDE THERAPY✓
90Y-DOTATE/DOTATOC✓
177Lu-DOTATE
✓mTOR inhibitors✓ Everolimus✓ Temsirolimus
✓TKI – Angiogenesis✓ Sunitinib✓Bevacizumab
✓CYTOTOXIC CHEMOTHERAPY✓ Streptozocin-based✓ Temozolomide-based
✓IMMUNOTHERAPY✓ Interferon✓PD-1 inh.
✓LIVER-DIRECTED THERAPY✓ TAE/TACE✓ SIRT
![Page 16: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/16.jpg)
ObjectiveResponse
PFS/OS
Heterogenous Studies
• Retrospective studies – Introduce bias
• ORR 0-38% mPFS 15-36 months mOS 25-50 months
• Overestimation of results
Van der Zwan W et al. Eur J Endocrinol 2015
![Page 17: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/17.jpg)
![Page 18: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/18.jpg)
PRIMARY ENDOPOINT: PROGRESSION-FREE SURVIVAL
![Page 19: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/19.jpg)
TTD was significantly longer in the 177Lu-Dotatate arm vs control: Global health status (HR 0.406), physical functioning (HR 0.518), role functioning (HR 0.580), fatigue (HR 0.621), pain (HR 0.566), diarrhea(HR 0.473), disease-related worries (HR, 0.572), and body image (HR, 0.425).Differences in median TTD were clinically significant in several domains: 28.8 months versus 6.1 months for global health status, and 25.2 months versus 11.5 months for physical functioning.
This analysis from the NETTER-1 phase III study demonstrates that, in addition to improving progression-free survival, 177Lu-Dotatate provides a significant QoL benefit for patients with progressive midgut NETs compared with high-dose octreotide.
![Page 20: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/20.jpg)
![Page 21: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/21.jpg)
![Page 22: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/22.jpg)
CATEGORIES OF TREATMENT
✓SOMATOSTATIN ANALOGUES✓Octreotide✓ Lanreotide
✓TELOTRISTAT
✓PEPTIDE RECEPTOR RADIONUCLIDE THERAPY✓
90Y-DOTATE/DOTATOC✓
177Lu-DOTATE
✓mTOR inhibitors✓ Everolimus✓ Temsirolimus
✓TKI – Angiogenesis✓ Sunitinib✓Bevacizumab
✓CYTOTOXIC CHEMOTHERAPY✓ Streptozocin-based✓ Temozolomide-based
✓IMMUNOTHERAPY✓ Interferon✓PD-1 inh.
✓LIVER-DIRECTED THERAPY✓ TAE/TACE✓ SIRT
![Page 23: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/23.jpg)
Patients with well-
differentiated (G1/G2),
advanced, progressive,
nonfunctional NET of lung
or GI origin (N = 302)
• Absence of active or any
history of carcinoid
syndrome
• Pathologically confirmed
advanced disease
• Enrolled within 6 months
from radiologic
progression
Everolimus 10 mg/day
N = 205
Treated until PD,
intolerable AE, or
consent withdrawal
2:1
R
A
N
D
O
M
I
Z
E
Placebo
N = 97
Endpoints:
• Primary: PFS (central)
• Key Secondary: OS
• Secondary: ORR, DCR, safety, HRQoL (FACT-G), WHO PS, NSE/CgA, PK
Stratified by:
• Prior SSA treatment (yes vs. no)
• Tumor origin (stratum A vs. B)*
• WHO PS (0 vs. 1)
*Based on prognostic level, grouped as: Stratum A (better prognosis) − appendix, caecum, jejunum,
ileum, duodenum, and NET of unknown primary. Stratum B (worse prognosis) − lung, stomach,
rectum, and colon except caecum.
Crossover to open label everolimus after progression in the placebo arm was not allowed prior to the
primary analysis.
Yao JC, et al. Lancet 2016
RADIANT-4 Study Design
![Page 24: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/24.jpg)
Primary Endpoint: PFS by Central Review Interim Overall Survival Analysis
![Page 25: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/25.jpg)
Neuroendocrine tumours of gastrointestinal orlung origin Afinitor is indicated for thetreatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours ofgastrointestinal or lung origin in adults withprogressive disease
APRIL 2016
On February 26, 2016, the U. S. Food and DrugAdministration approved everolimus (Afinitor ,Novartis) for the treatment of adult patientswith progressive, well-differentiated non-functional, neuroendocrine tumors (NET) ofgastrointestinal (GI) or lung origin withunresectable, locally advanced or metastaticdisease.
![Page 26: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/26.jpg)
CATEGORIES OF TREATMENT
✓SOMATOSTATIN ANALOGUES✓Octreotide✓ Lanreotide
✓TELOTRISTAT
✓PEPTIDE RECEPTOR RADIONUCLIDE THERAPY✓
90Y-DOTATE/DOTATOC✓
177Lu-DOTATE
✓mTOR inhibitors✓ Everolimus✓ Temsirolimus
✓TKI – Angiogenesis✓ Sunitinib✓Bevacizumab
✓CYTOTOXIC CHEMOTHERAPY✓ Streptozocin-based✓ Temozolomide-based
✓IMMUNOTHERAPY✓ Interferon✓PD-1 inh.
✓LIVER-DIRECTED THERAPY✓ TAE/TACE✓ SIRT
![Page 27: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/27.jpg)
Yao C et al. JCO 2017
![Page 28: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/28.jpg)
Treatment-NaiveN: 61
Previously-treatedN: 45
Overall Survival NA 33.8 months
Response Rate 21.3% 28.9%
Median durationResponse
19,1 months 14.7 months
Toxicity Grade 3-4
Neutropenia 20.8%
Diarrhoea 5,7%
HFS 6.6%
Thrombocytopenia 7.5%
Hypertension 5.7%
Raymond E et al. Neuroendocrinol 2018
![Page 29: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/29.jpg)
![Page 30: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/30.jpg)
![Page 32: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/32.jpg)
![Page 33: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/33.jpg)
Primary Endpoint: Progression-free survival by central review
![Page 34: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/34.jpg)
![Page 35: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/35.jpg)
![Page 36: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/36.jpg)
CATEGORIES OF TREATMENT
✓SOMATOSTATIN ANALOGUES✓Octreotide✓ Lanreotide
✓TELOTRISTAT
✓PEPTIDE RECEPTOR RADIONUCLIDE THERAPY✓
90Y-DOTATE/DOTATOC✓
177Lu-DOTATE
✓mTOR inhibitors✓ Everolimus✓ Temsirolimus
✓TKI – Angiogenesis✓ Sunitinib✓Bevacizumab
✓CYTOTOXIC CHEMOTHERAPY✓ Streptozocin-based✓ Temozolomide-based
✓IMMUNOTHERAPY✓ Interferon✓PD-1 inh.
✓LIVER-DIRECTED THERAPY✓ TAE/TACE✓ SIRT
![Page 37: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/37.jpg)
![Page 38: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/38.jpg)
![Page 39: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/39.jpg)
CATEGORIES OF TREATMENT
✓SOMATOSTATIN ANALOGUES✓Octreotide✓ Lanreotide
✓TELOTRISTAT
✓PEPTIDE RECEPTOR RADIONUCLIDE THERAPY✓
90Y-DOTATE/DOTATOC✓
177Lu-DOTATE
✓mTOR inhibitors✓ Everolimus✓ Temsirolimus
✓TKI – Angiogenesis✓ Sunitinib✓Bevacizumab
✓CYTOTOXIC CHEMOTHERAPY✓ Streptozocin-based✓ Temozolomide-based
✓IMMUNOTHERAPY✓ Interferon✓PD-1 inh.
✓LIVER-DIRECTED THERAPY✓ TAE/TACE✓ SIRT
![Page 40: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/40.jpg)
NENs have lower mutation rates than other cancers
Lawrence et al. Nature 2013
![Page 41: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/41.jpg)
RR 12% RR 6%
![Page 42: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/42.jpg)
Median age 59 years45% ECOG 1
≥2 lines – 67%PD-L1+ 16%
Median follow-up 18.6 months
Response Rate.- 3.7% (4 PR) – All PD-L1 -61 SD
mPFS 4.1 months6-months OS – 84.6%
20% G3-4 Toxicity (Fatigue + common)
Pembrolizumab monotherapy showed limited antitumor activity and manageable safety in pts with previously treated advanced NET
Strosberg J. ASCO-GI 2019
![Page 43: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/43.jpg)
Zhang et al. ESMO 2018
![Page 44: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/44.jpg)
Zhang et al. ESMO 2018
![Page 45: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/45.jpg)
Yao JC et al. ESMO 2018
![Page 46: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/46.jpg)
![Page 47: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/47.jpg)
Durvalumab plus Tremelimumab for the Treatment of Patients(pts) with Advanced Neuroendocrine Neoplasms (NENs) ofLung or Gastroenteropancreatic (GEP) Origin. A Phase IIMulticohort Trial (DUNE Trial / GETNE 1601)
DURVALUMAB 1500 mg every 28 days for 12
months
TREMELIMUMAB 75 mg every 28 days up to 4
doses
Efficacy and safety of Durvalumab plus Tremelimumab within four different cohorts: • Well-moderately differentiated lung NENs• Grade 1-2 gastrointestinal NENs• Grade 1-2 pancreatic NENs• Grade 3 GEP NENs
Primary endpoint for cohorts 1-3 is disease control rate at 9 months Primary endpoint for cohort 4 is median overall survivalCENTRAL RADIOLOGICAL REVIEW
Secondary endpoints: mPFS, survival, safety and tolerability and a wide panel of biomarkers in blood and tumor samples.
PI: J. Capdevila
![Page 48: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/48.jpg)
➢ SSA strengthen their long-term antiproliferative effect even in patients in progression
➢ Telotristat is useful in the control of diarrhea in carcinoid syndrome
➢ Radionuclide therapy (PRRT) increase efficacy in NENs maintaining QoL
➢ mTOR inhibitors (Everolimus) has shown efficacy in all types of NENs
➢ New TKI drugs in development (Pazopanib, Cabozantinib, Lenvatinib, Axitinib,
Sulfanitinib) with excellent results in phase II trials
➢ Combination TMZ + CAP > TMZ in panNENs (Phase IIR)
➢ Immunotherapy (antiPD1) fails to show activity in most of NENs
CONCLUSIONS
![Page 49: NOVEDADES EN NEOPLASIAS NEUROENDOCRINAS · functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. APRIL 2016. On. February 26, 2016,](https://reader034.vdocuments.us/reader034/viewer/2022050412/5f893e4edee45f5762235cdb/html5/thumbnails/49.jpg)